Almost every vial in the research-peptide market carries a version of the same sentence. It is treated as a single legal formula, printed as though the wording were fixed, and cited as though it settled something.
It is not one formula. There are two United States regulations that produce a research-use label, they cover different categories of product, they require different sentences, and the sentence most often printed matches neither. This page sets out both regulations from their own text, and reads FDA's own final guidance on the more permissive of the two — which says, at length, that the label is not what decides.
This is journalism about a labelling framework. It is not legal advice, and it cannot say where any particular seller or product sits.
Two regulations, and they are not alternatives
The drug regulation is 21 CFR 312.160, headed "Drugs for investigational use in laboratory research animals or in vitro tests." It authorises a specific kind of shipment and attaches four conditions to it. The label is the first; the other three are about the shipper's conduct — due diligence about the consignee, records naming the recipient kept for two years, and the return of unused supplies.
The diagnostics regulation is 21 CFR 809.10(c), part of the labelling rules for in vitro diagnostic products. It exempts certain shipments from the ordinary IVD labelling requirements if a prescribed statement appears prominently.
These are not two ways of saying the same thing. A drug substance shipped to a laboratory and a diagnostic reagent shipped to a laboratory are different articles under different parts of the Act, and each has its own sentence.
The two sentences, side by side
| 21 CFR 312.160 (drugs) | 21 CFR 809.10(c)(2)(i) (diagnostics) | |
|---|---|---|
| Required wording | "CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans." | "For Research Use Only. Not for use in diagnostic procedures." |
| What it excludes | Use in humans | Use in diagnostic procedures |
| Other conditions in the regulation | Consignee diligence, two-year records, return of unused supplies | None stated in paragraph (c) beyond the statement itself |
| Revocable by FDA? | Yes, under 312.160(b) | Not addressed in paragraph (c) |
The second row is the one that repays attention, because the two exclusions are not the same size. The drug caution excludes human use. The diagnostics statement excludes diagnostic use — a narrower thing. An RUO diagnostic reagent may perfectly well be used on human blood; what it may not do is produce a result a clinician acts on. Borrowing the diagnostics opening for a drug product imports the weaker exclusion and drops the stronger one.
There is a third statement in the same paragraph, for a later stage. Under 809.10(c)(2)(ii), a product undergoing pre-commercial testing must state: "For Investigational Use Only. The performance characteristics of this product have not been established." That is the IUO label, and it belongs to the same diagnostics pathway.
The sentence in the market belongs to neither
The wording that circulates on research-peptide vials and checkout pages is some variant of:
Research Use Only. Not for human consumption.
Set it against the two regulations. The first four words are the opening of the diagnostics statement at 809.10(c)(2)(i). The second half is not the diagnostics clause, which is about diagnostic procedures, and it is not the drug caution, which reads "Not for use in humans" and is preceded by a specific sentence naming a new drug for investigational use. Consumption is a food idiom; neither regulation uses it.
So a vial carrying the market sentence has done three things at once: invoked the diagnostics regulation by its opening, failed to complete that regulation's statement, and failed to print the caution that the drug regulation requires. If the material is a drug substance — and a peptide shipped for laboratory research is being handled under the drug regulation, not the diagnostics one — the required caution is the long one, and it has not been printed.
This is checkable in a minute on any storefront, and it is worth checking, because the sentence is usually presented as the reason the transaction is lawful.
FDA has already said the label is not the thing
The most useful document on this subject is not about peptides at all. In November 2013 FDA issued final guidance titled Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only, from the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research. It exists because manufacturers were printing the RUO statement on products they were in fact selling for clinical use.
Its reasoning transfers, because the question is identical: does printing the sentence make the sentence true?
FDA's answer, in its own words:
A product's intended use refers to the "objective intent" of those legally responsible for labeling the product, which may be determined by looking at the totality of circumstances surrounding the distribution of the article.
And then, more concretely, it lists evidence that would "appear to conflict with RUO or IUO labeling" — the label notwithstanding:
- performance claims, instructions for clinical interpretation, clinical information, or "product names, or descriptors that claim or suggest that the IVD product may be used for any clinical diagnostic use";
- statements suggesting that laboratories "can validate the test through their own procedures and subsequently offer it for clinical diagnostic use";
- solicitation of business from laboratories that "do not perform research or clinical studies", which FDA says "may be viewed as demonstrating its intent that its products be used for clinical purposes";
- provision of specialised technical support, such as "assistance in performing clinical validation".
The guidance is explicitly non-binding — every page carries the header "Contains Non-binding Recommendations" — and it is about diagnostics, not about peptide vials. What it establishes is FDA's stated method: the agency reads the label alongside how the product is named, described, promoted, supported and sold, and treats the whole picture as the evidence of intent.
That method is not unique to the guidance. It is 21 CFR 801.4, the intended-use regulation the guidance cites, and it applies across labelling law.
The certification checkbox, addressed by name
Many research-chemical storefronts gate the cart behind a tickbox: I certify that I am a qualified researcher and that these materials will not be used in humans.
FDA's guidance considered that exact mechanism, under the heading Use of a "certification program":
User certification programs, where users certify that they will not use RUO/IUO products in a manner inconsistent with the labeling, would be viewed as one factor to consider when assessing these circumstances. However, the existence of a certification program alone would not relieve manufacturers from their responsibilities to ensure that their labeling and distribution practices for RUO/IUO products are consistent with the product's RUO/IUO label.
Two things follow. The checkbox is not nothing — FDA counts it as a factor. And it is not a transfer: the obligation to keep labelling and distribution consistent stays with the party doing the distributing. That is the same allocation the drug regulation makes, where the duty to exercise due diligence about the recipient sits on the shipper.
What the label does not tell a buyer
Neither regulation says anything about what is in the vial.
Read both texts looking for a purity figure, an identity method, a sterility requirement, an endotoxin limit, a stability requirement or a manufacturing standard, and there is nothing to find. 312.160 governs a shipment; 809.10(c) governs a statement on a package. A vial can carry either label, correctly printed, and contain material of any purity — or a different substance entirely.
This is why a research-use label and a certificate of analysis answer different questions, and why neither substitutes for the other. What a certificate can and cannot establish is a separate subject, set out here.
What is genuinely established, and what is not
Established, from the regulatory text:
- Two distinct research-use labelling regimes exist, with different required wording.
- The drug regime attaches three conduct conditions to the label and makes the authorisation revocable.
- The diagnostics regime's statement excludes diagnostic use, not human use.
Established, from FDA's own final guidance on the diagnostics regime:
- FDA's stated approach is that the label does not by itself determine intended use.
- A user-certification programme is one factor and does not relieve the distributor.
Not established, and not claimed here:
- Where any particular seller or product sits. That is a question of fact about that seller.
- Whether FDA's diagnostics guidance would be applied to a drug substance. It addresses IVD products, and the reasoning it uses is general; the guidance itself is not.
- What the market sentence means in law. It is not wording either regulation prescribes, which is the observation this page makes; what a court or the agency would make of it is not something a publisher can determine.
What a reader can check in five minutes
Open any research-peptide storefront and compare its printed sentence against the two required texts above. Note which regulation, if any, the wording matches.
Then look for the other three conditions of the drug regulation. Does the seller state how it satisfies itself that the recipient conducts laboratory tests? Does it say it keeps records naming the recipient? Does it describe returning unused material? The label is the visible condition; the other three are the ones that describe a research supply channel rather than a shop.
Related on this site
- Are peptides legal? — the four conditions of 21 CFR 312.160 read in full, and what FDA has said about named compounds
- 503A vs 503B — the two compounding permissions, which are a different framework entirely
- How to read a certificate of analysis — what a COA certifies and the four things it does not
- FDA warning letters to peptide sellers — what enforcement has actually addressed
Sources and dates
- 21 CFR 312.160, Drugs for investigational use in laboratory research animals or in vitro tests. Read 14 September 2026.
- 21 CFR 809.10(c), Labeling for in vitro diagnostic products — paragraphs (c)(1), (c)(2)(i) and (c)(2)(ii), via the Legal Information Institute. Read 14 September 2026.
- 21 CFR 801.4, Meaning of intended uses. Cited at footnote 9 of the guidance below.
- FDA, Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and Food and Drug Administration Staff. Final guidance, issued November 2013; CDRH and CBER. Full text downloaded and read 14 September 2026. Quotations are from sections IV.B, IV.C.1 and V.